Drug targets and predictive biomarkers in the management of metastatic melanoma
Jaykumar Thumar, Eva Giesen, Harriet M KlugerYale Cancer Center, Yale School of Medicine, New Haven, CT, USAAbstract: Melanoma is the leading cause of fatal skin cancer, and in the past few decades, there has been an increase in the incidence of and mortality from metastatic melanoma. Until recently...
Saved in:
Main Authors: | Thumar J (Author), Giesen E (Author), Kluger HM (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2012-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Molecular targeted therapies in metastatic melanoma
by: Chakraborty R, et al.
Published: (2013) -
Treatment of BRAF-Mutated Metastatic Melanoma: Immunotherapy or Target Therapy?
by: Ana Sofia Rodrigues, et al.
Published: (2021) -
Body composition is prognostic and predictive of ipilimumab activity in metastatic melanoma
by: Michael P. Chu, et al.
Published: (2020) -
Metastatic melanoma - a review of current and future drugs
by: Tiago Rodrigues Velho
Published: (2012) -
Biomarkers Predicting for Response and Relapse with Melanoma Systemic Therapy
by: Sarah J. Welsh, et al.
Published: (2020)